Financial terms of the agreement have not been disclosed.
FBMFarma will be responsible for obtaining regulatory approval, marketing and distribution in Brazil.
Ampio CEO Michael Macaluso said that FBMFarma was the ideal partner for Ampio in Brazil.
FBM group marketing director Alexandre Ferreira said that HOSPFAR actively sells into both the private and public markets in the country, responding to almost all Brazilian Government tenders.
"FBM group executives are very pleased to establish this partnership with Ampio, since they are extremely confident and enthusiastic about the success that Zertane will have in the Brazilian market," Ferreira added.